CDK4 and neoplasm: Asghar U.S. et al. concluded in a systematic review in 2022 that tumor profiling and next-generation sequencing (NGS) of liquid biopsies performed before starting CDK4/6 inhibition could be beneficial to clearly identify poorly responding patients [76].